Genocea Biosciences Inc (NASDAQ:GNCA) has been given an average recommendation of “Hold” by the six research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $5.83.
Several brokerages have recently weighed in on GNCA. Zacks Investment Research cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Piper Jaffray Companies reiterated an “overweight” rating and set a $5.00 price objective on shares of Genocea Biosciences in a research note on Thursday, November 2nd.
Shares of Genocea Biosciences (NASDAQ:GNCA) traded down $0.01 on Friday, hitting $0.91. 507,812 shares of the stock traded hands, compared to its average volume of 1,365,113. Genocea Biosciences has a 52-week low of $0.79 and a 52-week high of $7.29. The stock has a market cap of $77.14, a PE ratio of -0.42 and a beta of 1.94. The company has a debt-to-equity ratio of 2.51, a current ratio of 1.55 and a quick ratio of 1.55.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameriprise Financial Inc. raised its stake in shares of Genocea Biosciences by 11.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 2,300 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $100,000. Rhumbline Advisers bought a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $157,000. New York State Common Retirement Fund bought a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $159,000. Finally, OxFORD Asset Management LLP bought a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $204,000. Hedge funds and other institutional investors own 34.33% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Analysts Set Genocea Biosciences Inc (GNCA) Price Target at $5.83” was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/30/analysts-set-genocea-biosciences-inc-gnca-price-target-at-5-83.html.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.